Allakos Inc. (ALLK)
0.27
-0.01 (-3.50%)
At close: Mar 03, 2025, 3:59 PM
0.26
-2.68%
After-hours: Mar 03, 2025, 05:40 PM EST
No 1D chart data available
| Bid | 0.24 |
| Market Cap | 23.98M |
| Revenue (ttm) | 10.79M |
| Net Income (ttm) | -179.39M |
| EPS (ttm) | -2.03 |
| PE Ratio (ttm) | -0.13 |
| Forward PE | -0.41 |
| Analyst | Hold |
| Ask | 0.28 |
| Volume | 652,948 |
| Avg. Volume (20D) | 2,358,067 |
| Open | 0.28 |
| Previous Close | 0.28 |
| Day's Range | 0.26 - 0.29 |
| 52-Week Range | 0.23 - 1.66 |
| Beta | 0.77 |
About ALLK
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 19, 2018
Employees 131
Stock Exchange NASDAQ
Ticker Symbol ALLK
Website https://www.allakos.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ALLK stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 645.16% from the latest price.
Buy 33.33%
Hold 66.67%
Sell 0.00%
1 month ago
-80.47%
Allakos shares are trading lower after the company...
Unlock content with
Pro Subscription
4 months ago
+1.37%
Allakos shares are trading higher after the company announced results from the Phase 1 study of subcutaneous AK006 in healthy volunteers.
